The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -29,438,613 |
| Stock-based compensation | 2,441,875 |
| Depreciation | 245,747 |
| Amortization of right of use asset | 118,754 |
| Tax receivable | -2,059,507 |
| Prepaid expenses and other current assets | 286,729 |
| Accounts payable and accrued expenses | 1,027,161 |
| Operating lease liability | -98,006 |
| Net cash used in operating activities | -23,930,304 |
| Purchase of property and equipment | 732,925 |
| Purchase of short-term investments | 6,480,860 |
| Net cash used in investing activities | -7,213,785 |
| Payments of deferred offering costs | 136,999 |
| Proceeds from exercise of stock options | 6,342 |
| Proceeds from exercise of stock warrants | 124,800 |
| Proceeds from sale of common stock, net of offering costs | 107,392,716 |
| Net cash provided by financing activities | 107,386,859 |
| Effect of foreign currency on cash | 3,842 |
| Net change in cash and cash equivalents | 76,246,612 |
| Cash and cash equivalents - beginning of year | 17,681,954 |
| Cash and cash equivalents - end of year | 93,928,566 |
Immix Biopharma, Inc. (IMMX)
Immix Biopharma, Inc. (IMMX)